Skip to main content
Stonvex
Loading…
Home
Markets
Screener
Portfolio
Community
Stonvex publishes market data and research only.
Not investment advice. Not a registered investment advisor.
Read disclaimer
.
Stonvex
Search...
Cmd K
Search...
Cmd K
← Back to rankings
OTLK
Live
Save
Overview
Financials
Filings
Earnings Calls
Short Interest
Ownership
Ratings
Peers
News
Log in
Get Started
Loading latest news…
☁️ News word cloud
Top words across the last 50 articles for this ticker.
nasdaq
outlook
therapeutics
after
stocks
announced
bevacizumab
trading
treatment
today
2024
penny
ophthalmic
formulation
nyse
gained
approval
climbed
rating
diseases
OTLK
Outlook Therapeutics, Inc. Common Stock
52w low +69.5%
StonvexStonvexStonvexStonvex